These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alglucerase: the debate continues. Push S Pharmacoeconomics; 1995 Mar; 7(3):268-9. PubMed ID: 10155316 [No Abstract] [Full Text] [Related]
3. [Cost reduction in the treatment of Gaucher s disease]. García Salom P; Acedo A Farm Hosp; 2007; 31(3):194-5. PubMed ID: 17941761 [No Abstract] [Full Text] [Related]
4. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. Clarke JT; Amato D; Deber RB CMAJ; 2001 Sep; 165(5):595-6. PubMed ID: 11563212 [No Abstract] [Full Text] [Related]
5. [Financing of enzyme treatment in Gaucher disease]. Wisløff F Tidsskr Nor Laegeforen; 2003 Feb; 123(3):364. PubMed ID: 12640908 [No Abstract] [Full Text] [Related]
6. The cost of treating Gaucher disease. Beutler E Nat Med; 1996 May; 2(5):523-4. PubMed ID: 8616707 [No Abstract] [Full Text] [Related]
7. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease. Whittington R; Goa KL Pharmacoeconomics; 1995 Jan; 7(1):63-90. PubMed ID: 10155294 [TBL] [Abstract][Full Text] [Related]
9. Why Genzyme can charge so much for Cerezyme. Anand G Wall St J (East Ed); 2005 Nov; ():A15. PubMed ID: 16502533 [No Abstract] [Full Text] [Related]
10. Low-dose versus high-frequency regimens in Gaucher's disease. Maródi L Lancet; 1995 Nov; 346(8987):1434. PubMed ID: 7475855 [No Abstract] [Full Text] [Related]
11. [Gaucher's disease. Forget the past?]. Giralt M; Félix DR Sangre (Barc); 1994 Feb; 39(1):1-2. PubMed ID: 8197512 [No Abstract] [Full Text] [Related]
12. Alglucerase for Gaucher's disease: dose, costs and benefits. Beutler E; Garber AM Pharmacoeconomics; 1994 Jun; 5(6):453-9. PubMed ID: 10147261 [No Abstract] [Full Text] [Related]
13. Lysosomal storage diseases: natural history and ethical and economic aspects. Beutler E Mol Genet Metab; 2006 Jul; 88(3):208-15. PubMed ID: 16515872 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Gaucher's disease. Freiwald DR N Engl J Med; 1993 May; 328(21):1566. PubMed ID: 8479499 [No Abstract] [Full Text] [Related]
15. Management of Gaucher disease in a post-communist transitional health care system: Croatian experience. Mrsić M; Stavljenić-Rukavina A; Fumić K; Labar B; Bogdanić V; Potocki K; Kardum-Skelin I; Rovers D Croat Med J; 2003 Oct; 44(5):606-9. PubMed ID: 14515422 [TBL] [Abstract][Full Text] [Related]
16. In brief: Velaglucerase (Vpriv) for Gaucher's disease. Med Lett Drugs Ther; 2010 May; 52(1337):36. PubMed ID: 20431522 [No Abstract] [Full Text] [Related]
17. Economic malpractice in the treatment of Gaucher's disease. Beutler E Am J Med; 1994 Jul; 97(1):1-2. PubMed ID: 8030649 [No Abstract] [Full Text] [Related]
18. Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day. Wall St J (East Ed); 2005 Nov; ():A1, A15. PubMed ID: 16502532 [No Abstract] [Full Text] [Related]
19. Competing for the treasure in exceptions. Cox TM Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870 [No Abstract] [Full Text] [Related]